Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses
Research and development costs	$ 1,219,339	$ 63,302	$ 2,295,826	$ 134,259
General and administrative expenses	2,123,834	426,532	10,864,696	1,959,785
Depreciation and amortization	173,696		484,355
Total operating expenses	3,516,869	489,834	13,644,877	2,094,044
Loss from Operations	(3,516,869)	(489,834)	(13,644,877)	(2,094,044)
Other income (expense)
Interest expense	(370)	(75,501)	(5,191)	(388,143)
Change in fair value of warrant liabilities	804,833		7,077,376
Inducement expense			(298,714)
Total other income (expense)	804,463	(75,501)	6,773,471	(388,143)
Net Loss	(2,712,406)	(565,335)	(6,871,406)	(2,482,187)
Other comprehensive gain (loss)
Foreign currency translation	(6,510)	(7,310)	(4,036)	(30,077)
Comprehensive loss	$ (2,718,916)	$ (572,645)	$ (6,875,442)	$ (2,512,264)
Net loss per share – basic and diluted	$ (0.12)	$ (0.10)	$ (0.34)	$ (0.43)
Weighted average shares outstanding, basic and diluted	23,142,780	5,861,727	20,325,782	5,733,360